Furan-2-carboxylic acid
Furan-2-carboxylic acid, an orally active selective human cathepsin K inhibitor, may have the therapeutic potential for the treatment of diseases characterized by excessive bone loss including osteoporosis.Furan-2-carboxylic acid also has anti-bacterial effect, inhibits the proliferation of some slow-growing or difficult-to-culture bacteria on the plates.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Oncol Lett.2020, 20(4):122.
J Ethnopharmacol.2020, 249:112396
Nutrients.2023, 15(12):2644.
The Japan Society for Analytical Chemistry2017, 613-617
J Pharmaceut Biomed2020, 182:113110
Front Pharmacol.2022, 13:870553.
Am J Chin Med.2016, 44(6):1255-1271
Pharmacol Rep.2017, 69(6):1224-1231
Front Pharmacol.2020, 11:566490.
South African J of Botany2020, 135:50-57
Related and Featured Products
PLoS One. 2012;7(7):e41142.
Trace amounts of furan-2-carboxylic acids determine the quality of solid agar plates for bacterial culture.[Pubmed:
22848437]
Many investigators have recognised that a significant proportion of environmental bacteria exist in a viable but non-culturable state on agar plates, and some researchers have also noticed that some of such bacteria clearly recover their growth on matrices other than agar. However, the reason why agar is unsuitable for the growth of some bacteria has not been addressed.
METHODS AND RESULTS:
According to the guide of a bioassay for swarming inhibition,We identified 5-hydroxymethylFuran-2-carboxylic acid (5-HMFA) and Furan-2-carboxylic acid (FA) as factors that inhibit bacterial swarming and likely inhibit extracellular polysaccharide production on agar. The Furan-2-carboxylic acids 5-HMFA and Furan-2-carboxylic acid effectively inhibited the swarming and swimming of several environmental bacteria at concentrations of 1.8 and 2.3 µg L(-1) (13 and 21 nmol L(-1)), respectively, which are equivalent to the concentrations of these compounds in 0.3% agar. On Luria-Bertani (LB) plates containing 1.0% agar that had been previously washed with MeOH, a mixture of 5-HMFA and Furan-2-carboxylic acid in amounts equivalent to their original concentrations in the unwashed agar repressed the swarming of Escherichia coli K12 strain W3110, a representative swarming bacterium.
CONCLUSIONS:
Agar that contains trace amounts of 5-HMFA and Furan-2-carboxylic acid inhibits the proliferation of some slow-growing or difficult-to-culture bacteria on the plates, but it is useful for single colony isolation due to the ease of identification of swarmable bacteria as the non-swarmed colonies.
J Pharmacol Exp Ther. 2006 Aug;318(2):555-62.
An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.[Pubmed:
16699068]
Human cathepsin K, a cysteine proteinase of the papain family, has been recognized as a potential drug target for the treatment of osteoporosis. The predominant expression of cathepsin K in osteoclasts has rendered the enzyme into a major target for the development of novel antiresorptive drugs.
METHODS AND RESULTS:
Now, we report the pharmacological properties of OST-4077 [Furan-2-carboxylic acid (1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide] as a novel selective cathepsin K inhibitor. Human and rat cathepsin K were inhibited in vitro by Furan-2-carboxylic acid with the IC50 values of 11 and 427 nM, respectively. Furan-2-carboxylic acid suppressed bone resorption induced by rabbit osteoclasts (IC50, 37 nM) but did not affect bone mineralization or cellular alkaline phosphatase activity in MC3T3-E1 cells. Parathyroid hormone-induced bone resorption was inhibited in a dose-dependent manner in thyroparathyroidectomized rats gavaged with a single dose of Furan-2-carboxylic acid (ED50, 69 mg/kg). When given orally twice daily for 4 weeks to 3-month-old ovariectomized (OVX) rats, Furan-2-carboxylic acid dose-dependently prevented bone loss, as monitored by bone densitometry, ash content, and urinary excretion of deoxypyridinoline. No change in serum osteocalcin in the OVX rats by Furan-2-carboxylic acid suggested that bone formation might not be affected by the agent.
CONCLUSIONS:
In summary, Furan-2-carboxylic acid selectively inhibited bone resorbing activities of osteoclasts and prevented bone loss induced by estrogen deficiency but did not affect bone formation. Furan-2-carboxylic acid, an orally active selective human cathepsin K inhibitor, may have the therapeutic potential for the treatment of diseases characterized by excessive bone loss including osteoporosis.
